Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients.

Arthritis Research & Therapy
Caroline CharpinRené Gérolami

Abstract

Reactivation of hepatitis B virus (HBV) infection in patients with past infection has been described in 5% to 10% of individuals undergoing immunosuppressive therapies. No data are available to date on the outcome of patients treated by tumour necrosis factor-alpha (TNFalpha) inhibitors for chronic arthritis with a serological pattern of past HBV infection. The aim of our study was to monitor HBV markers in HBV surface antigen (HBsAg)-negative/anti-HBcAb-positive patients treated with a TNFalpha inhibitor for inflammatory arthritides. Twenty-one HBsAg-negative/anti-HBcAb-positive patients were included. HBV serological patterns were compared with those determined before starting TNFalpha inhibitors. Serum HBV DNA testing by polymerase chain reaction was additionally performed. Spearman correlation analysis was used and P < 0.05 was chosen as the significance threshold. Before starting therapy, mean anti-HBsAb titre was 725 IU/L, no patient had an anti-HBsAb titre <10 IU/L, and 18 patients had an anti-HBsAb >100 IU/L. At a mean time of 27.2 months following therapy introduction, mean anti-HBsAb titre was 675 IU/L and anti-HBsAb titre remained >100 IU/L in 17 patients. There was a strong correlation between the first and second a...Continue Reading

References

Oct 29, 2005·Arthritis and Rheumatism·Joachim ListingAngela Zink
Jul 26, 2006·Clinical Rheumatology·Grigorios T Sakellariou, Ioannis Chatzigiannis
Jun 15, 2007·Rheumatology·G RafteryD Kane
Dec 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Winnie YeoPaul K S Chan

❮ Previous
Next ❯

Citations

Feb 22, 2012·Medizinische Klinik, Intensivmedizin und Notfallmedizin·P LehmannM Fleck
Mar 30, 2013·World Journal of Gastroenterology : WJG·Pilar López-SerranoMaria Dolores Sánchez-Tembleque
Aug 8, 2014·Current Hepatology Reports·Anil SeetharamRobert Gish
Dec 10, 2014·Best Practice & Research. Clinical Rheumatology·Percival D Sampaio-Barros, Irene E van der Horst-Bruinsma
Feb 1, 2012·Clinical Journal of Gastroenterology·Hiromasa OhiraAtsushi Takahashi
Dec 23, 2011·Expert Opinion on Biological Therapy·Mauro ViganòMassimo Colombo
Mar 15, 2012·Expert Opinion on Biological Therapy·Tim L Jansen, C J J Mulder
Jan 30, 2015·Expert Opinion on Drug Safety·Giuseppe MurdacaFrancesco Puppo
Jan 29, 2011·Expert Opinion on Biological Therapy·Matthew B Carroll
Jun 26, 2012·Journal of the American Academy of Dermatology·Amanda AbramsonRobert Perrillo
Aug 21, 2015·The Tohoku Journal of Experimental Medicine·Ryu WatanabeHideo Harigae
Jan 24, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Michele BaroneGiovanni Lapadula
Dec 14, 2011·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Eiji Tanaka, Yukitomo Urata
Aug 24, 2010·Journal of the European Academy of Dermatology and Venereology : JEADV·R NavarroE Daudén
Sep 13, 2015·Best Practice & Research. Clinical Rheumatology·Worawit Louthrenoo
Oct 15, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·D FocosiF Scatena
May 9, 2012·Nature Reviews. Rheumatology·Dimitrios Vassilopoulos, Leonard H Calabrese
Sep 12, 2018·The Annals of Pharmacotherapy·Rhiannon M BathKellie J Goodlet
Apr 5, 2011·The Journal of Rheumatology·Chiara GiannittiMauro Galeazzi
Feb 9, 2019·Alimentary Pharmacology & Therapeutics·Uday N ShivajiNeeraj Bhala
Feb 2, 2019·Expert Opinion on Drug Safety·Giuseppe MurdacaFrancesco Puppo
Feb 28, 2019·International Journal of Rheumatic Diseases·Chak Sing LauSwan Sim Yeap

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Related Concepts

Related Feeds

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.